score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	KIRP-A4-8311	TCGA-A4-8311-01	
Putatively Actionable	Clinical trial			Copy Number	PIK3CA	Amplification				0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily).	Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86.	https://doi.org/10.1158/1078-0432.CCR-14-0947													0				PIK3CA Amplification	1.0	KIRP-A4-8311	TCGA-A4-8311-01	
Putatively Actionable	Clinical evidence			Copy Number	EGFR	Amplification				0.0	0.0		Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793													0				EGFR Amplification	1.0	KIRP-A4-8311	TCGA-A4-8311-01	
Putatively Actionable		Clinical evidence		Copy Number	BRAF	Amplification				0.0	0.0									Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	Amplification of BRAF may predict resistance to RAF inhibition.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				BRAF Amplification		KIRP-A4-8311	TCGA-A4-8311-01	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.2						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (20%)		KIRP-A4-8311		
Biologically Relevant				Copy Number	POT1	Amplification				0.0	0.0																					0				POT1 Amplification		KIRP-A4-8311	TCGA-A4-8311-01	
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		KIRP-A4-8311	TCGA-A4-8311-01	
Biologically Relevant				Copy Number	EZH2	Amplification				0.0	0.0																					0				EZH2 Amplification		KIRP-A4-8311	TCGA-A4-8311-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PMS2 Amplification, PRDM2 p.703_704insP (Insertion)		KIRP-A4-8311		
Biologically Relevant				Mutational Signature	COSMIC Signature 16	version 2	0.298																									0				COSMIC Signature (version 2) 16 (30%)		KIRP-A4-8311		
